Purpose: Co-mutations of the KRAS and STK11 genes in advanced non-small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. While neoadjuvant chemoimmunotherapy is now a standard of care treatment for resectable...
Conclusions: First results from a real-world population confirm promising efficacy of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC. Patients with co-occurring KEAP1 mutations seem to derive less benefit. 结论:来自真实人群的一...
今日,美国FDA宣布,加速批准安进(Amgen)公司开发的Lumakras(sotorasib)上市,用于治疗肿瘤携带KRASG12C突变的非小细胞肺癌(NSCLC)患者。这些患者至少接受过一种前期全身性治疗。这是首款靶向任何KRAS基因突变的抗癌疗法。 KRAS基因突变是癌症患者中最常见的致癌基因突变之一。然而它也是著名的“不可成药”靶点,Lumakras的...
Based on two large meta-analyses, KRAS mutation appears to be a weak negative prognostic factor in NSCLC; however, this was not confirmed in a recent pooled analysis from four clinical trials of adjuvant chemotherapy for early stage lung cancer (LACE-BIO study). Furthermore, different types ...
RAS突变发生部位及KRAS突变亚型的发生比例；NSCLC以G12C为主，胰腺癌和结直肠癌则以G12D和G12V为主1...
Nat Commun2015;6:6744.15. Luo J. KRAS mutation in pancreatic cancer. Semin Oncol2021;48:10-8.16. Nakajima EC, Drezner N, Li X, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res2022;28:1482-6.想了解更多精彩内容，快来关注BioArt生物艺术 ...
The therapeutic schedule depends mostly on the stage and mutation type. As illustrated above, the efficacy of monotreatment of immunotherapy is controversial in NSCLC patients; thus, researchers have begun investigating the combinational strategy of immunotherapy and other therapies. In this section, we...
Liver function tests should be monitored prior to treatment initiation. If a patient develops liver damage, sotorasib should be withheld, dose reduced or permanently discontinued. References FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy. ...
as the first treatment for adult patients with NSCLC whose tumours harbour KRAS (G12C) mutations and who have received at least one prior systemic therapy130. This is a milestone because it is the first drug to directly target mutated KRAS. The full Phase I cohort (n = 129) receiving...
Toggle Sidebar Find Previous Next Presentation ModeOpenPrintDownloadCurrent View Tools Zoom Out Zoom In Automatic ZoomActual SizePage FitPage Width50%75%100%125%150%200%300%400%